Which has stronger valuation and earnings, CABA or KLRA?

Cabaletta Bio is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A

Is CABA or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Kailera Therapeutics N/A N/A N/A

Does the media prefer CABA or KLRA?

In the previous week, Cabaletta Bio had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 6 mentions for Cabaletta Bio and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.77 beat Cabaletta Bio's score of 0.57 indicating that Kailera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CABA or VCEL?

Vericel has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A Vericel $276.26M 7.45 $16.52M $0.47 85.51

Is CABA or VCEL more profitable?

Vericel has a net margin of 7.91% compared to Cabaletta Bio's net margin of 0.00%. Vericel's return on equity of 6.91% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Vericel 7.91% 6.91% 5.02%

Does the media refer more to CABA or VCEL?

In the previous week, Vericel had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 7 mentions for Vericel and 6 mentions for Cabaletta Bio. Vericel's average media sentiment score of 1.41 beat Cabaletta Bio's score of 0.57 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, COAG or CABA?

Cabaletta Bio is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A -$24.78 N/A Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A

Is COAG or CABA more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Cabaletta Bio N/A -128.27% -95.47%

Does the media prefer COAG or CABA?

In the previous week, Cabaletta Bio had 4 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for Cabaletta Bio and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 1.43 beat Cabaletta Bio's score of 0.57 indicating that Hemab Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CABA or ADMA?

In the previous week, ADMA Biologics had 4 more articles in the media than Cabaletta Bio. MarketBeat recorded 10 mentions for ADMA Biologics and 6 mentions for Cabaletta Bio. ADMA Biologics' average media sentiment score of 1.08 beat Cabaletta Bio's score of 0.57 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, CABA or NBTX?

Nanobiotix has higher revenue and earnings than Cabaletta Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A Nanobiotix $36.87M 53.27 -$27.11M N/A N/A

Is CABA or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Nanobiotix N/A N/A N/A

Does the media favor CABA or NBTX?

In the previous week, Cabaletta Bio had 3 more articles in the media than Nanobiotix. MarketBeat recorded 6 mentions for Cabaletta Bio and 3 mentions for Nanobiotix. Cabaletta Bio's average media sentiment score of 0.57 beat Nanobiotix's score of 0.42 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cabaletta Bio (CABA) Competitors

$3.47 -0.01 (-0.29%)

As of 09/4/2026 04:00 PM Eastern

Compare

CABA vs. KLRA, VCEL, COAG, ADMA, and NBTX

Should you buy Cabaletta Bio stock or one of its competitors? Cabaletta Bio's main competitors and comparable companies include Kailera Therapeutics (KLRA), Vericel (VCEL), Hemab Therapeutics (COAG), ADMA Biologics (ADMA), and Nanobiotix (NBTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cabaletta Bio compare to Kailera Therapeutics?

Cabaletta Bio (NASDAQ:CABA) and Kailera Therapeutics (NASDAQ:KLRA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Cabaletta Bio presently has a consensus price target of $15.33, suggesting a potential upside of 341.88%. Kailera Therapeutics has a consensus price target of $42.75, suggesting a potential upside of 163.40%. Given Cabaletta Bio's higher probable upside, equities analysts plainly believe Cabaletta Bio is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Kailera Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Kailera Therapeutics	N/A	N/A	N/A

Cabaletta Bio is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

In the previous week, Cabaletta Bio had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 6 mentions for Cabaletta Bio and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.77 beat Cabaletta Bio's score of 0.57 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Kailera Therapeutics beats Cabaletta Bio on 5 of the 8 factors compared between the two stocks.

How does Cabaletta Bio compare to Vericel?

Cabaletta Bio (NASDAQ:CABA) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Cabaletta Bio presently has a consensus price target of $15.33, indicating a potential upside of 341.88%. Vericel has a consensus price target of $58.40, indicating a potential upside of 45.31%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Cabaletta Bio is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Vericel has a net margin of 7.91% compared to Cabaletta Bio's net margin of 0.00%. Vericel's return on equity of 6.91% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Vericel	7.91%	6.91%	5.02%

Vericel has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Vericel	$276.26M	7.45	$16.52M	$0.47	85.51

In the previous week, Vericel had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 7 mentions for Vericel and 6 mentions for Cabaletta Bio. Vericel's average media sentiment score of 1.41 beat Cabaletta Bio's score of 0.57 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cabaletta Bio has a beta of 3.27, indicating that its stock price is 227% more volatile than the broader market. Comparatively, Vericel has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

Summary

Vericel beats Cabaletta Bio on 9 of the 14 factors compared between the two stocks.

How does Cabaletta Bio compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Cabaletta Bio (NASDAQ:CABA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Cabaletta Bio is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

Hemab Therapeutics' return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Cabaletta Bio	N/A	-128.27%	-95.47%

Hemab Therapeutics currently has a consensus target price of $51.40, indicating a potential upside of 15.74%. Cabaletta Bio has a consensus target price of $15.33, indicating a potential upside of 341.88%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Cabaletta Bio had 4 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for Cabaletta Bio and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 1.43 beat Cabaletta Bio's score of 0.57 indicating that Hemab Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cabaletta Bio beats Hemab Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Cabaletta Bio compare to ADMA Biologics?

Cabaletta Bio (NASDAQ:CABA) and ADMA Biologics (NASDAQ:ADMA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

ADMA Biologics has a net margin of 32.98% compared to Cabaletta Bio's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
ADMA Biologics	32.98%	40.17%	26.97%

ADMA Biologics has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
ADMA Biologics	$510.17M	4.22	$146.93M	$0.70	13.74

In the previous week, ADMA Biologics had 4 more articles in the media than Cabaletta Bio. MarketBeat recorded 10 mentions for ADMA Biologics and 6 mentions for Cabaletta Bio. ADMA Biologics' average media sentiment score of 1.08 beat Cabaletta Bio's score of 0.57 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cabaletta Bio presently has a consensus target price of $15.33, suggesting a potential upside of 341.88%. ADMA Biologics has a consensus target price of $18.67, suggesting a potential upside of 94.04%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts clearly believe Cabaletta Bio is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

75.7% of ADMA Biologics shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cabaletta Bio has a beta of 3.27, meaning that its stock price is 227% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Summary

ADMA Biologics beats Cabaletta Bio on 10 of the 16 factors compared between the two stocks.

How does Cabaletta Bio compare to Nanobiotix?

Cabaletta Bio (NASDAQ:CABA) and Nanobiotix (NASDAQ:NBTX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

38.8% of Nanobiotix shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cabaletta Bio has a beta of 3.27, meaning that its share price is 227% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Nanobiotix's return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Nanobiotix	N/A	N/A	N/A

Nanobiotix has higher revenue and earnings than Cabaletta Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Nanobiotix	$36.87M	53.27	-$27.11M	N/A	N/A

In the previous week, Cabaletta Bio had 3 more articles in the media than Nanobiotix. MarketBeat recorded 6 mentions for Cabaletta Bio and 3 mentions for Nanobiotix. Cabaletta Bio's average media sentiment score of 0.57 beat Nanobiotix's score of 0.42 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cabaletta Bio currently has a consensus price target of $15.33, indicating a potential upside of 341.88%. Nanobiotix has a consensus price target of $37.33, indicating a potential downside of 3.78%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Cabaletta Bio beats Nanobiotix on 8 of the 13 factors compared between the two stocks.

Get Cabaletta Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CABA vs. The Competition

Export

Metric	Cabaletta Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$588.32M	$4.00B	$7.25B	$12.91B
Dividend Yield	N/A	3.60%	2.54%	9.14%
P/E Ratio	-2.21	12.71	273.54	25.43
Price / Sales	N/A	1,346.68	625.10	95.06
Price / Cash	N/A	45.00	28.92	35.62
Price / Book	2.99	16.43	11.01	6.39
Net Income	-$167.86M	-$22.85M	$3.49B	$358.69M
7 Day Performance	11.22%	0.31%	1.04%	-0.14%
1 Month Performance	25.72%	7.97%	5.39%	0.94%
1 Year Performance	104.12%	49.26%	24.18%	14.02%

Cabaletta Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CABA Cabaletta Bio	2.351 of 5 stars	$3.47 -0.3%	$15.33 +341.9%	+104.1%	$588.32M	N/A	N/A	50	Analyst Forecast
KLRA Kailera Therapeutics	2.8837 of 5 stars	$15.40 -5.0%	$42.75 +177.6%	N/A	$2.10B	N/A	N/A	145	News Coverage
VCEL Vericel	3.7071 of 5 stars	$39.90 -2.6%	$58.40 +46.4%	+18.0%	$2.10B	$276.26M	84.90	300	Positive News
COAG Hemab Therapeutics	3.055 of 5 stars	$45.73 +2.0%	$51.40 +12.4%	N/A	$2.09B	N/A	N/A	72	News Coverage Positive News Gap Down
ADMA ADMA Biologics	3.8329 of 5 stars	$9.39 +0.5%	$18.67 +98.8%	-43.0%	$2.09B	$510.17M	13.41	530	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CABA) was last updated on 9/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cabaletta Bio (CABA) Competitors

CABA vs. KLRA, VCEL, COAG, ADMA, and NBTX

How does Cabaletta Bio compare to Kailera Therapeutics?

Summary

How does Cabaletta Bio compare to Vericel?

Summary

How does Cabaletta Bio compare to Hemab Therapeutics?

Summary

How does Cabaletta Bio compare to ADMA Biologics?

Summary

How does Cabaletta Bio compare to Nanobiotix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cabaletta Bio (CABA) Competitors

CABA vs. KLRA, VCEL, COAG, ADMA, and NBTX

How does Cabaletta Bio compare to Kailera Therapeutics?

Do analysts rate CABA or KLRA?

Is CABA or KLRA more profitable?

Which has stronger valuation and earnings, CABA or KLRA?

Does the media prefer CABA or KLRA?

Summary

How does Cabaletta Bio compare to Vericel?

Do analysts recommend CABA or VCEL?

Is CABA or VCEL more profitable?

Which has preferable valuation & earnings, CABA or VCEL?

Does the media refer more to CABA or VCEL?

Which has more volatility & risk, CABA or VCEL?

Summary

How does Cabaletta Bio compare to Hemab Therapeutics?

Which has better valuation & earnings, COAG or CABA?

Is COAG or CABA more profitable?

Do analysts rate COAG or CABA?

Does the media prefer COAG or CABA?

Summary

How does Cabaletta Bio compare to ADMA Biologics?

Is CABA or ADMA more profitable?

Which has better earnings & valuation, CABA or ADMA?

Does the media favor CABA or ADMA?

Do analysts prefer CABA or ADMA?

Do insiders & institutionals believe in CABA or ADMA?

Which has more volatility & risk, CABA or ADMA?

Summary

How does Cabaletta Bio compare to Nanobiotix?

Do institutionals and insiders believe in CABA or NBTX?

Which has more risk and volatility, CABA or NBTX?

Is CABA or NBTX more profitable?

Which has higher valuation & earnings, CABA or NBTX?

Does the media favor CABA or NBTX?

Do analysts prefer CABA or NBTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools